Myriad Genetics, Inc. · NASDAQ:MYGN

Myriad Genetics — Q2 2022 Earnings Presentation

16 slides from Myriad Genetics's earnings presentation, Aug 4, 2022

  1. Slide 1: Myriad Genetics Second Quarter 2022 Earnings

    Myriad Genetics Second Quarter 2022 Earnings August 4, 2022

  2. Slide 2: Forward looking statements

    Forward looking statements Some of the information These statements are based on management’s current expectations and the actual presented here today may events or results may differ materially and adversely from these expectations. We contain projections or refer you to the documents the Company f

  3. Slide 3: Who we are, what we do, and why it matters

    Who we are, what we do, and why it matters Illuminating the path to better health through genetic insights. Our purpose-led Mission We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. Our Vision As a leader in genetic testing and precision

  4. Slide 4: Second quarter operating and financial highlights

    Second quarter operating and financial highlights 1 2 3 4 5 Total revenue of Diagnostic test GAAP gross margin GAAP operating loss Diluted GAAP $179.3 million volumes of 260,000 was 72.3%; in the quarter was earnings per share of increased 7% increased 9% YoY improving 70 basis $17.8 million; $(0.18

  5. Slide 5: Strategic priorities

    Strategic priorities A trusted, differentiated partner with specialized expertise Innovation that improves clinical Enterprise capabilities to accelerate Focus on execution and delivery of outcomes, ease of use, and access growth and scale to market opportunity consistent results Developing and enha

  6. Slide 6: Nicole Lambert, Chief Operating Officer

    Nicole Lambert, Chief Operating Officer

  7. Slide 7: Mental Health

    Mental Health Using genetic insights to help physicians understand Quarterly highlights how genetic alterations • GeneSight reported its highest quarterly volume level ever, up 39% impact patient response to year-over-year antidepressants and other • Approximately 99% of GeneSight tests Mental were

  8. Slide 8: Women's Health

    Women’s Health Leading health and Quarterly highlights wellness with best-in- • Presented at the 2022 American Society of Clinical Oncology annual class genetic insights for meeting, highlighting our market- women of all ancestries, leading hereditary cancer test, MyRisk assessing cancer risk Women’

  9. Slide 9: Oncology

    Oncology Clarifying cancer Quarterly highlights treatment with genetic • MyChoice CDx reported its highest quarterly volume level ever, up 63% insights and companion year-over-year diagnostic tests that • BRACAnalysis CDx reported double- Women’s digit percent volume growth are designed to work Onco

  10. Slide 10: Bryan Riggsbee, Chief Financial Officer

    Bryan Riggsbee, Chief Financial Officer

  11. Slide 11: Consolidated quarterly highlights

    Consolidated quarterly highlights Revenue excluding divested assets, adjusted gross margin, adjusted operating income, adjusted EPS Quarter ended *In millions June 2022 March 2022 June 2021 Revenue* $179.3 $164.6 $168.3 Annual change 7% 11% — Adjusted gross margin 72.4% 71.1% 72.1% Annual change 30

  12. Slide 12: Second quarter 2022 revenue and test performance

    Second quarter 2022 revenue and test performance Year over Year % Sequential % Revenue Test Volume Revenue Test Volume Hereditary cancer (8%) (4%) 12% 7% Prenatal 13% (4%) 4% 1% Pharmacogenomics 46% 39% 13% 13% Tumor profiling 11% 7% 3% 5% Overall company (5%) (3%) 9% 7% Overall company 7% 9% 9% 7%

  13. Slide 13: Fiscal year 2022 financial guidance

    Fiscal year 2022 financial guidance (in millions, except per share amounts) Revenue Updated $670 - $700 Previous $670 - $700 Change No change Gross Margin % Updated 70% - 72% Previous 70% - 72% Change No change GAAP Adjusted* (Non-GAAP) Operating Expenses Updated $585 - $595 $490 - $500 Previous $55

  14. Slide 14: Myriad strengths and strategic advantages

    Myriad strengths and strategic advantages Significant market growth in focused business areas Leader in genetic testing and precision medicine Industry • Successfully implementing transformation and leading Best-in-class growth strategy operating product quality margins & • Broad and growing commerc

  15. Slide 15: Myriad Genetics Health. Illuminated.

    Myriad genetics Health. Illuminated.

  16. Slide 16: Thank you

    Thank you ©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com

Myriad Genetics — Q2 2022 Earnings Presentation on 6ix